Omalizumab for asthma [8]

New England Journal of Medicine

Volumn 355, Issue 12, 2006, Pages 1281-1282

  Winchester, David E ^a   Jacob, Ashok ^a   Murphy, Tom ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN E; METHYLPREDNISOLONE; OMALIZUMAB; PREDNISOLONE; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANAMNESIS; ASTHMA; BLOOD LEVEL; CASE REPORT; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; HUMAN; HUMAN TISSUE; LETTER; MALE; PRIORITY JOURNAL; SKIN BIOPSY; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; NOTE; PATHOLOGY; SKIN;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHURG-STRAUSS SYNDROME; HUMANS; MALE; MIDDLE AGED; SKIN;

EID: 33748910403     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc061914     Document Type: Letter

References (4)

1. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006;354:2689-95.
2. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998;279:455-7.
3. Stirling RG, Chung KF. Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun. Thorax 1999;54:865-6.
4. Kobayashi S, Ishizuka S, Tamura N, Takaya M, Kaneda K, Hashimoto H. Churg-Strauss syndrome (CSS) in a patient receiving pranlukast. Clin Rheumatol 2003;22:491-2.